HIV treatment showdown: could simpler drug regimens reduce inflammation?
NCT ID NCT05699785
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at HIV patients over 40 (or those on HIV therapy for over 10 years) who switched to either a three-drug or a two-drug antiretroviral regimen. Researchers will measure markers of inflammation in the blood and track how many patients develop other health conditions over three years. The goal is to see if a simpler, two-drug therapy leads to less inflammation and fewer comorbidities than the standard three-drug approach.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
antiretroviral therapy (bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir/lamivudine)
What this could lead to
If successful, this could help doctors choose the best HIV treatment regimen to reduce long-term inflammation and lower the risk of other health problems.
What could go wrong
This is an observational study, not a controlled trial, so it can show links but not prove cause and effect. Results may not apply to all HIV patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH Simone VEIL
Cannes, 06614, France
-
CHU Nice
Nice, France